Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

Fig. 4

Mean plasma concentration–time profiles of BPI-9016M and its main metabolites (M1 and M2-2). A: Plasma concentration–time curve of BPI-9016M PK assessed in Cycle 1 Day 28 of dose-expansion phase at 648 h, 649 h, 650 h, 652 h, 654 h, 656 h, 660 h, 672 h, 696 h, 720 h after Cycle 1 first dose of BPI-9016M. B: Plasma concentration–time curve of M1 PK assessed in Cycle 1 Day 28 of dose-expansion phase at 648 h, 649 h, 650 h, 652 h, 654 h, 656 h, 660 h, 672 h, 696 h, 720 h after Cycle 1 first dose of BPI-9016M. C: Plasma concentration–time curve of M2-2 PK assessed in Cycle 1 Day 28 of dose-expansion phase at 648 h, 649 h, 650 h, 652 h, 654 h, 656 h, 660 h, 672 h, 696 h, 720 h after Cycle 1 first dose of BPI-9016M

 QD quaque die, PK pharmacokinetics

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us